Cisplatin and Vinorelbine vs Ifosfamide and Epirubicin in Lung Cancer
Author Information
Author(s): G Colucci, V Gebbia, D Galetta, F Riccardi, S CarieIIo, N Gebbia
Primary Institution: Oncological Institute, Bari, Italy
Hypothesis
The study tests the 'worst drug rule' hypothesis, suggesting that using a less active regimen first can improve outcomes when followed by a more active regimen.
Conclusion
The combination of Cisplatin and Vinorelbine is more effective than Ifosfamide and Epirubicin in treating advanced non-small-cell lung cancer.
Supporting Evidence
- Overall response rate was 47% for the Cisplatin and Vinorelbine group compared to 21% for the Ifosfamide and Epirubicin group.
- Stage III patients showed a significant response rate of 55% for Cisplatin and Vinorelbine versus 14% for Ifosfamide and Epirubicin.
- Median overall survival was 9 months for the Cisplatin and Vinorelbine group compared to 7 months for the Ifosfamide and Epirubicin group.
Takeaway
Doctors tested two different chemotherapy sequences for lung cancer, and found that starting with Cisplatin and Vinorelbine worked better than starting with Ifosfamide and Epirubicin.
Methodology
A multicentric, prospective phase III randomized study comparing two chemotherapy sequences in patients with advanced non-small-cell lung cancer.
Limitations
The study did not reach the planned sample size of 102 patients, and the enrollment period was limited.
Participant Demographics
The majority of participants were men, with a median age of around 64 years.
Statistical Information
P-Value
P=0.0112
Confidence Interval
95% CL 33-61%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website